Is there an alternative to quality-adjusted life years for supporting healthcare decision making?

References

• Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Oper Res. 1980;28:206–223.
   Web of Science ®Google Scholar
• Duru G, Auray JP, Beresniak A, et al. Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics. 2002;20:463–473.
   PubMed Web of Science ®Google Scholar
• Lipscomb J, Drummond M, Fryback D, et al. Retaining, and enhancing, the QALY. Value Health. 2009;12:S18–S26.
   PubMedGoogle Scholar
• Beresniak A, Auray JP, Lamure M, et al. About the robustness of theoretical foundations of QALY. Estudios de Economia Aplicada. 2006;24-3:685–696.
   Google Scholar
• Beresniak A, Russell AS, Haraoui B, et al. Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol. 2007;34:2193–2200.
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
   Google Scholar
• Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000;21:587–611.
   PubMed Web of Science ®Google Scholar
• Mc Gregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoeconomics. 2006;24:947–952.
   PubMed Web of Science ®Google Scholar
• PPACA. The patient protection and affordable care act [Internet]. 2010;PL111-148:3–23 [cited 2010 Mar 23]. Available from: https://en.wikipedia.org/wiki/Patient_Protection_and_Affordable_Care_Act
   Google Scholar
• IQWIG. General methods for the assessment of the relation of benefits to cost [Internet]. Ger Inst Qual Efficiency Health Care. 2009;19. Available from: http://www.ispor.org/peguidelines/source/Germany_AssessmentoftheRelationofBenefitstoCosts_En.pdf
   Google Scholar
• Neumann PJ. What next for QALYs? JAMA. 2011;305:1806–1807.
   PubMed Web of Science ®Google Scholar
• Guidelines for the economic evaluation of health technologies: Canada [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. [cited 2006 Dec 31] Available from: http://www.inahta.org/wp-content/themes/inahta/img/AboutHTA_Guidelines_for_the_Economic_Evaluation_of_Health_Technologies.pdf
   Google Scholar
• Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60:1571–1582.
   PubMed Web of Science ®Google Scholar
• Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality adjusted life-years by different preference-based instruments. Med Care. 2003;41:791–801.
   PubMed Web of Science ®Google Scholar
• Buckingham KJ, Devlin NJ. A note on the nature of utility in time and health and implications for cost utility analysis. Soc Sci Med. 2009;68:362–367.
   PubMed Web of Science ®Google Scholar
• Holmes D. Report triggers quibbles over QALYs, a staple of health metrics. Nat Med. 2013;19:248.
   PubMed Web of Science ®Google Scholar
• Beresniak A, Medina-Lara A, Auray JP, et al. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project. Pharmacoeconomics. 2015;33(1):61–69.
   PubMed Web of Science ®Google Scholar
• Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429–445.
   Web of Science ®Google Scholar
• Murray CJ, Barber RM, Foreman KJ. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;28:2145–2191.
   Google Scholar
• Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9:142–149.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Torrance G, Furlong W, Feeny D, et al. Multi-attribute preference functions. Health utilities index. Pharmacoeconomics. 1995;7:503–520.
   PubMed Web of Science ®Google Scholar
• Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol. 1998;51:1115–1128.
   PubMed Web of Science ®Google Scholar
• Hawthorne G, Richardson J, NAm D. A comparison of the assessment of quality of life (AQoL) with four other generic utility instruments. Ann Med. 2001;33:358–370.
   PubMed Web of Science ®Google Scholar
• Hill C. Health related quality of life measurement. Euro Style Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Gafni A, Birch S. Searching for a common currency: critical appraisal of the scientific basis underlying European harmonization of the measurement of health related quality of life (EuroQol). Health Policy. 1994;28:67–69.
   PubMedGoogle Scholar
• Roy B. Méthodologie Multicritère d’aide à la Décision. Economica. 1985. Paris.
   Google Scholar
• Roy B, Bouyssou D. Aide Multicritère à la Décision: Méthodes et Cas. Economica. 1993. Paris.
   Google Scholar
• Vincke P. Multicriteria decision-aid. New York (NY): John Wiley & Sons; 1992.
   Google Scholar
• Beresniak A. Public health. Be prepared: what work in fight against flu. Health Serv J. 2014;124:19–21.
   PubMedGoogle Scholar
• McIntosh E. Using discrete choice experiments within a cost-benefit analysis framework: some considerations. Pharmacoeconomics. 2006;24:855–868.
   PubMed Web of Science ®Google Scholar
• Briand S, Beresniak A, Nguyen T, et al. Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach. PLoS Negl Trop Dis. 2009;3:e483.
   Google Scholar
• Just J, Belfar S, Wanin S, et al. Impact of innate and environmental factors on wheezing persistence during childhood. J Asthma. 2010;47:412–416.
   PubMed Web of Science ®Google Scholar
• Terris-Prestholt F, Quaife M, Vickerman P. Parameterising user uptake in economic evaluations: the role of discrete choice experiments. Health Econ. 2016 Feb 25;25:116–123.
   PubMed Web of Science ®Google Scholar
• Howard K, Jan S, Rose JM, et al. Community preferences for the allocation of donor organs for transplantation: a discrete choice study. Transplantation. 2015;99:560–567.
   PubMed Web of Science ®Google Scholar
• Antal P, Fannes G, Timmerman D, et al. Using literature and data to learn Bayesian networks as clinical models of ovarian tumors. Artif Intell Med. 2004;30:257–281.
   PubMed Web of Science ®Google Scholar
• Gevaert O, De Smet F, Timmerman D, et al. Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks. Bioinformatics. 2006;22:184–190.
   Web of Science ®Google Scholar
• Heckerman D. A tutorial on learning with Bayesian networks. MSR-TR-95-06. 1995; Redmond (WA): Microsoft Research. p. 57. Available from: http://research.microsoft.com/en-us/um/people/heckerman/tutorial.pdf
   Google Scholar
• Cawson MR, Mitchell SA, Knight C, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord. 2014;15:26.
   Google Scholar
• Kobayashi H, Ohnishi T, Nakagawa R, et al. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: a Bayesian network meta-analysis. Int J Geriatr Psychiatry. 2015 Dec 17.
   Google Scholar
• Beresniak A, Bertherat E, Perea W, et al. A Bayesian network approach to the study of historical epidemiological databases: modelling meningitis outbreaks in the Niger. Bull World Health Organ. 2012;90:412–417A.
   PubMed Web of Science ®Google Scholar